Read + Share
Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS
wild-type metastatic colorectal cancer. Eur J Cancer 2020;138:1-10.
PMID: 32818762
|
 |
|
Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS
wild-type metastatic colorectal cancer. Eur J Cancer 2020;138:1-10.
PMID: 32818762
|
|
|
|